恒瑞医药签署瑞康曲妥珠单抗项目授权许可协议 有资格获得最高10.93亿美元里程碑付款

Core Viewpoint - Heng Rui Medicine has entered into an agreement with Glenmark Specialty S.A. to license its innovative drug SHR-A1811, expanding its global market reach and enhancing its international performance [1][2] Group 1: Agreement Details - Heng Rui will grant Glenmark Specialty exclusive rights to develop and commercialize SHR-A1811 outside of specific regions including mainland China, Hong Kong, Macau, Taiwan, the USA, Canada, Europe, Japan, Russia, and several Central Asian countries [1] - Glenmark Specialty will pay an upfront fee of $18 million to Heng Rui, with potential milestone payments related to registration and sales reaching up to $1.093 billion [1] - Sales royalties will be paid to Heng Rui based on the sales performance of SHR-A1811 within the licensed territories [1] Group 2: Strategic Implications - The agreement is expected to broaden the overseas market for SHR-A1811, providing high-quality treatment options for global patients [2] - The company aims to enhance its innovative brand and international performance through a combination of independent research and open collaboration [2] - By leveraging partnerships with leading international firms, the company seeks to accelerate the transformation of its research outcomes and maximize product value for global patients [2]